Abstract
Anti-CD3 monoclonal antibodies (mAbs) produced by hybridomas were initially used for transplant rejection treatment. Due to its potential ability to induce immune tolerance, attempts were made to use these mAbs by other therapeutic areas, such as autoimmune diseases control. However, most of anti-CD3 mAb were murine derivatives and highly immunogenic in humans, which hampered its broader …